Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20837138 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Yang NY, et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23, 201-12 20837138
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 no change compared to control
ephrin A1 decrease ephrin A1 Fc
augment treatment-induced decrease
imatinib ephrin A1 no effect upon treatment-induced decrease
dasatinib ephrin A1 no effect upon treatment-induced decrease
PP2 ephrin A1 augment treatment-induced decrease
ephrin A1 HRas (human) decrease wild-type HRas
ephrin A1 HRas (human) no effect upon treatment-induced decrease constitutively active HRas
ephrin A1 RRas (human) no effect upon treatment-induced decrease wild-type RRas
ephrin A1 RRas (human) no effect upon treatment-induced decrease constituvely active RRas
Mn(2+) ephrin A1 no effect upon treatment-induced decrease
ephrin A1 no effect upon treatment-induced decrease anti-alpha-beta1 integrin
ephrin A1 inhibit treatment-induced decrease constitutively active PIK3CA
ephrin A1 SHIP-2 (human) no effect upon treatment-induced decrease
ephrin A1 Akt1 (human) no effect upon treatment-induced decrease wild-type Akt
ephrin A1 Akt1 (human) inhibit treatment-induced decrease Myr Akt
ephrin A1 PHLPP (human) no effect upon treatment-induced decrease PHLPP1siRNA no effect
ephrin A1 PHLPP2 (human) no effect upon treatment-induced decrease PHLPP2 siRNA no effect
calyculin A ephrin A1 inhibit treatment-induced decrease
tautomycin ephrin A1 inhibit treatment-induced decrease
okadaic acid ephrin A1 inhibit treatment-induced decrease

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
IgG increase
decrease ephrin A4 Fc
increase ephrin A2 mAb
ephrin A1 decrease ephrin A2 siRNA increase
decrease ephrin A4 Fc (ephrin A2 siRNA increase)
decrease ephrin A2 mAb (ephrin A2 siRNA increase)
dasatinib ephrin A1 no effect upon treatment-induced decrease
imatinib ephrin A1 no effect upon treatment-induced decrease
PP2 ephrin A1 augment treatment-induced decrease
ephrin A1 HRas (human) no effect upon treatment-induced decrease wild-type HRas
HRas (human) no effect upon treatment-induced decrease constitutively active HRas
Mn(2+) ephrin A1 no effect upon treatment-induced decrease
no effect upon treatment-induced decrease anti-alpha-beta1 integrin
ephrin A1 PIK3CA (human) inhibit treatment-induced decrease constitutively active PIK3CA
SHP-2 (human) no effect upon treatment-induced decrease
Akt1 (human) inhibit treatment-induced decrease wild-type Akt
ephrin A1 Akt1 (human) no effect upon treatment-induced decrease Myr Akt
ephrin A1 PHLPP (human) no effect upon treatment-induced decrease PHLPP siRNA no effect
PHLPP2 (human) no effect upon treatment-induced decrease PHLPP2 siRNA no effect
calyculin A ephrin A1 inhibit treatment-induced decrease
tautomycin inhibit treatment-induced decrease
okadaic acid ephrin A1 inhibit treatment-induced decrease

Y221-p - CRK (human)
Orthologous residues
CRK (human): Y221‑p, CRK iso2 (human): , CRK (mouse): Y221‑p, CRK iso3 (mouse): , CRK (rat): Y221‑p, CRK (chicken): Y222‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 increase ephrin A1 Fc
imatinib ephrin A1 inhibit treatment-induced increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
increase Ephrin A2 siRNA inhibits
decrease ephrin A2 mAb
increase ephrin A2 siRNA inhibits
HRas (human) decrease wild-type HRas
ephrin A1 HRas (human) increase constitutively active HRas

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
increase Ephrin A2 siRNA inhibits
decrease ephrin A2 mAb
increase ephrin A2 siRNA inhibits
HRas (human) decrease wild-type HRas
ephrin A1 HRas (human) increase constitutively active HRas

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
increase Ephrin A2 siRNA inhibits
decrease ephrin A2 mAb
increase ephrin A2 siRNA inhibits
HRas (human) decrease wild-type HRas
ephrin A1 HRas (human) increase constitutively active HRas

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
increase Ephrin A2 siRNA inhibits
decrease ephrin A2 mAb
increase ephrin A2 siRNA inhibits
HRas (human) decrease wild-type HRas
ephrin A1 HRas (human) increase constitutively active HRas

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin A1 decrease ephrin A1 Fc
ethanol no change compared to control
LY294002 decrease
rapamycin decrease
PD98059 increase
calyculin A ephrin A1 inhibit treatment-induced decrease
ephrin A1 increase ephrin A1 Fc
imatinib ephrin A1 inhibit treatment-induced increase

Y419-p - Src (human)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines

T1462-p - TSC2 (human)
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ethanol increase
LY294002 decrease
rapamycin no change compared to control
PD98059 no change compared to control
ephrin A1 decrease
dasatinib ephrin A1 no effect upon treatment-induced decrease
imatinib ephrin A1 no effect upon treatment-induced decrease
PP2 ephrin A1 augment treatment-induced decrease
ephrin A1 RRas (human) no effect upon treatment-induced decrease wild-type RRas
ephrin A1 RRas (human) no effect upon treatment-induced decrease constitutively active RRas
ephrin A1 no effect upon treatment-induced decrease constitutively active PIK3CA
calyculin A ephrin A1 inhibit treatment-induced decrease
tautomycin ephrin A1 inhibit treatment-induced decrease
okadaic acid ephrin A1 inhibit treatment-induced decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.